Global Molecular Diagnostics Market Size, Share, Growth: By Product & Service: Instruments, Reagents & Kits, Services & Software; By Test Location: Point-of-Care, Self-test or Over the Counter, Central Laboratories; By Technology; By Application; By End User; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Molecular Diagnostics Market Overview 
    3.1    Global Molecular Diagnostics Market Historical Value (2017-2023) 
    3.2    Global Molecular Diagnostics Market Forecast Value (2024-2032)
4    Global Molecular Diagnostics Market Landscape
    4.1    Global Molecular Diagnostics: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Type
        4.1.3    Analysis by Indication
    4.2    Global Molecular Diagnostics: Product Landscape
        4.2.1    Analysis by Product & Service
        4.2.2    Analysis by Technology 
        4.2.3    Analysis by Application 
5    Global Molecular Diagnostics Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Molecular Diagnostics Market Segmentation (2017-2032)
    6.1    Global Molecular Diagnostics Market (2017-2032) by Product & Service
        6.1.1    Market Overview
        6.1.2    Instruments
        6.1.3    Reagents & Kits
        6.1.4    Services & Software
    6.2    Global Molecular Diagnostics Market (2017-2032) by Test Location
        6.2.1    Market Overview
        6.2.2    Point-of-Care
        6.2.3    Self-test or Over the Counter
        6.2.4    Central Laboratories
    6.3    Global Molecular Diagnostics Market (2017-2032) by Technology
        6.3.1    Market Overview
        6.3.2    Polymerase Chain Reaction (PCR) 
        6.3.3    In Situ Hybridization
        6.3.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        6.3.5    Chips and Microarrays
        6.3.6    Mass Spectrometry
        6.3.7    Sequencing
        6.3.8    Transcription Mediated Amplification
        6.3.9    Others
    6.4    Global Molecular Diagnostics Market (2017-2032) by Application
        6.4.1    Market Overview
        6.4.2    Oncology
            6.4.2.1    Breast Cancer
            6.4.2.2    Colorectal Cancer
            6.4.2.3    Lung Cancer
            6.4.2.4    Prostate Cancer
            6.4.2.5    Other Cancers
        6.4.3    Pharmacogenomics
        6.4.4    Infectious Diseases
            6.4.4.1    Hepatitis
            6.4.4.2    HIV
            6.4.4.3    CT/NG
            6.4.4.4    Hospital Acquired Infections (HAI)
            6.4.4.5    HPV
            6.4.4.6    Tuberculosis
            6.4.4.7    Influenza
            6.4.4.8    Other Infectious Diseases
        6.4.5    Genetic Testing
        6.4.6    Neurological Diseases
        6.4.7    Cardiovascular Diseases
        6.4.8    Microbiology
        6.4.9    Others
    6.5    Global Molecular Diagnostics Market (2017-2032) by End User
        6.5.1    Market Overview
        6.5.2    Diagnostic Laboratories
        6.5.3    Hospitals & Clinics
        6.5.4    Other End Users
    6.6    Global Molecular Diagnostics Market (2017-2032) by Region
        6.6.1    Market Overview
        6.6.2    North America
        6.6.3    Europe 
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Molecular Diagnostics Market (2017-2032)
    7.1    North America Molecular Diagnostics Market (2017-2032) by Product and Service 
        7.1.1    Market Overview    
        7.1.1    Instruments
        7.1.2    Reagents & Kits
        7.1.3    Services & Software 
    7.2    North America Molecular Diagnostics Market (2017-2032) by Technology
        7.2.1    Market Overview
        7.2.2    Polymerase Chain Reaction (PCR) 
        7.2.3    In Situ Hybridization
        7.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        7.2.5    Chips and Microarrays
        7.2.6    Mass Spectrometry
        7.2.7    Sequencing
        7.2.8    Transcription Mediated Amplification
        7.2.9    Others
    7.3    North America Molecular Diagnostics Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Molecular Diagnostics Market (2017-2032)
    8.1    Europe Molecular Diagnostics Market (2017-2032) by Product and Service
        8.1.1    Market Overview    
        8.1.2    Instruments
        8.1.3    Reagents & Kits
        8.1.4    Services & Software 
    8.2    Europe Molecular Diagnostics Market (2017-2032) by Technology
        8.2.1    Market Overview
        8.2.2    Polymerase Chain Reaction (PCR) 
        8.2.3    In Situ Hybridization
        8.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        8.2.5    Chips and Microarrays
        8.2.6    Mass Spectrometry
        8.2.7    Sequencing
        8.2.8    Transcription Mediated Amplification
        8.2.9    Others
    8.3    Europe Molecular Diagnostics Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Molecular  Diagnostics Market (2017-2032)
    9.1    Asia Pacific Molecular Diagnostics Market (2017-2032) by Product and Service
        9.1.1    Market Overview    
        9.1.2    Instruments
        9.1.3    Reagents & Kits
        9.1.4    Services & Software 
    9.2    Asia Pacific Molecular Diagnostics Market (2017-2032) by Technology
        9.2.1    Market Overview
        9.2.2    Polymerase Chain Reaction (PCR) 
        9.2.3    In Situ Hybridization
        9.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        9.2.5    Chips and Microarrays
        9.2.6    Mass Spectrometry
        9.2.7    Sequencing
        9.2.8    Transcription Mediated Amplification
        9.2.9    Others
    9.3    Asia Pacific Molecular Diagnostics Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Molecular Diagnostics Market (2017-2032)
    10.1     Latin America Molecular Diagnostics Market (2017-2032) by Product and Service
        10.1.1    Market Overview    
        10.1.2    Instruments
        10.1.3    Reagents & Kits
        10.1.4    Services & Software 
    10.2    Latin America Molecular Diagnostics Market (2017-2032) by Technology
        10.2.1    Market Overview
        10.2.2    Polymerase Chain Reaction (PCR) 
        10.2.3    In Situ Hybridization
        10.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        10.2.5    Chips and Microarrays
        10.2.6    Mass Spectrometry
        10.2.7    Sequencing
        10.2.8    Transcription Mediated Amplification
        10.2.9    Others
    10.3    Latin America Molecular Diagnostics Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa  Molecular Diagnostics Market (2017-2032)
    11.1    Middle East and Africa Molecular Diagnostics Market (2017-2032) by Product and Service
        11.1.1    Market Overview    
        11.1.2    Instruments
        11.1.3    Reagents & Kits
        11.1.4    Services & Software 
    11.2    Middle East and Africa Molecular Diagnostics Market (2017-2032) by Technology
        11.2.1    Market Overview
        11.2.2    Polymerase Chain Reaction (PCR) 
        11.2.3    In Situ Hybridization
        11.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        11.2.5    Chips and Microarrays
        11.2.6    Mass Spectrometry
        11.2.7    Sequencing
        11.2.8    Transcription Mediated Amplification
        11.2.9    Others
    11.3    Middle East and Africa Molecular Diagnostics Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1     Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent  Analysis
    13.1    Analysis by Type of Patent
    13.2    Analysis by Publication Year
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Patent Age
    13.5    Analysis by CPC Analysis
    13.6    Analysis by Patent Valuation 
    13.7    Analysis by Key Players
14    Grants Analysis
    14.1    Analysis by Year
    14.2    Analysis by Amount Awarded
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Grant Application
    14.5    Analysis by Funding Institute
    14.6    Analysis by NIH Departments
    14.7    Analysis by Recipient Organization 
15    Clinical Trials Analysis
    15.1     Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area
    15.5    Analysis by Geography
16    Funding  and Investment Analysis
    16.1    Analysis by Funding Instances
    16.2    Analysis by Type of Funding
    16.3    Analysis by Funding Amount
    16.4    Analysis by Leading Players
    16.5    Analysis by Leading Investors
    16.6    Analysis by Geography
17    Partnership and Collaborations Analysis
    17.1    Analysis by Partnership Instances
    17.2    Analysis by Type of Partnership
    17.3    Analysis by Leading Players
    17.4    Analysis by Geography
18    Supplier Landscape
    18.1    Market Share by Top 5 Companies
    18.2    BioMérieux SA 
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisition
        18.2.5    Certifications
    18.3    BD
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisition
        18.3.5    Certifications
    18.4    Bio-Rad Laboratories, Inc.
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisition
        18.4.5    Certifications
    18.5    Abbott 
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisition
        18.5.5    Certifications
    18.6    Agilent Technologies, Inc.
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisition
        18.6.5    Certifications
    18.7    Hologic Inc.
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisition
        18.7.5    Certifications
    18.8    Danaher Corporation
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisition
        18.8.5    Certifications
    18.9    DiaSorin
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisition
        18.9.5    Certifications
    18.10    Illumina, Inc.
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisition
        18.10.5    Certifications
    18.11    Johnson & Johnson Services, Inc.
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisition
        18.11.5    Certifications
    18.12    QIAGEN N.V.
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisition
        18.12.5    Certifications
    18.13    F. Hoffmann-La Roche, Ltd.
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisition
        18.13.5    Certifications
    18.14    PerkinElmer, Inc.
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisition
        18.14.5    Certifications
    18.15    Siemens Healthineers
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisition
        18.15.5    Certifications
    18.16    Thermo Fisher Scientific Inc.
        18.16.1    Financial Analysis
        18.16.2    Product Portfolio
        18.16.3    Demographic Reach and Achievements
        18.16.4    Mergers and Acquisition
        18.16.5    Certifications
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)
    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.